MG
TVTX icon

Marex Group’s Travere Therapeutics TVTX Stock Holding History

Marex Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$208K Sell
3,664
-14,563
-80% -$646K ﹤0.01% 1002
2026
Q1 		$542K Buy
18,227
+11,543
+173% +$345K ﹤0.01% 604
2025
Q4 		$255K Buy
+6,684
New +$217K ﹤0.01% 760

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group's TVTX Position: Q2 2026 in Review

Marex Group reduced its Travere Therapeutics (TVTX) stake by 80% in Q2 2026, selling an estimated $646K and leaving 3,664 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #1002.

Marex Group first reported a position in TVTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $542K in Q1 2026. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Marex Group held 3,664 shares of Travere Therapeutics worth $208K as of Q2 2026.
  • Marex Group sold 14,563 Travere Therapeutics shares in Q2 2026, an estimated $646K.
  • Travere Therapeutics made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #1002 holding.
  • Marex Group first reported a position in Travere Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Marex Group's Travere Therapeutics position peaked at $542K in Q1 2026.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.